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The activity of DC-159a, a novel orally administered fluorinated quinolone, was evaluated by reference broth
microdilution or agar dilution methods against 1,149 recently collected clinical isolates from five continents.
Against pathogens associated with community-acquired respiratory tract infections (CA-RTIs), the MIC90s
were 0.12 g/ml for Streptococcus pneumoniae, 0.015 to 0.03 g/ml for Haemophilus influenzae, 0.03 g/ml for
Moraxella catarrhalis, and 0.12 g/ml for beta-hemolytic streptococci. Similarly, DC-159a was potent against
various types of staphylococci (MIC90 range, 0.03 to 2 g/ml), Enterococcus faecalis (MIC90, 4 g/ml), wild-type
isolates of the family Enterobacteriaceae (MIC90 range, 0.06 to 2 g/ml), wild-type Pseudomonas aeruginosa
(MIC90, 2 g/ml), and Acinetobacter spp. (MIC90, 0.12 g/ml). Fluoroquinolone-nonsusceptible organism
subsets usually had elevated DC-159a MICs, but the MICs were often two- to fourfold lower than those of
levofloxacin and moxifloxacin. In conclusion, DC-159a appears to possess a balanced broad spectrum of
activity that exceeds the activities of the currently marketed fluoroquinolones, especially against pathogens
that cause CA-RTIs.
The emergence of resistance among commonly isolated
pathogens has compromised the clinical utility of several major
antimicrobial classes, including the -lactams, macrolides, ami-
noglycosides, glycopeptides, and fluoroquinolones (1, 7, 12,
14). For the fluoroquinolones, the modifications of the DNA
gyrase and topoisomerase targets (7) can elevate the gatifloxa-
cin, gemifloxacin, levofloxacin, and moxifloxacin MICs into the
resistant ranges for Streptococcus pneumoniae isolates and,
more rarely, Haemophilus influenzae and Moraxella catarrhalis
isolates. Similarly, important gram-positive pathogens (staph-
ylococci, beta-hemolytic streptococci, enterococci) and gram-
negative bacilli (members of the family Enterobacteriaceae,
Pseudomonas spp.) have consistently acquired resistance to the
fluoroquinolones by prolonged exposure (1, 13, 14). The need
for novel agents in this class has become critical for continued
access to agents with clinical activity and for the provision of
agents with a balance of potencies against species of emerging
pathogens (multidrug-resistant [MDR] Acinetobacter spp. and
Stenotrophomonas maltophilia) while offering continued cover-
age against pneumococci, Staphylococcus aureus, and other
community-acquired pathogens (10, 13).
DC-159a is a novel orally administered fluoroquinolone de-
veloped by Daiichi Pharmaceutical Co., Ltd. (Tokyo, Japan),
and has been reported to have a residual affinity for strains
with mutations in the quinolone resistance-determining region
(QRDR) (2, 9). Such features (10) provide this agent with a
focus of activity against community-acquired pathogens that
cause significant occurrences of respiratory tract infections,
uncomplicated cutaneous infections, and possibly, other infec-
tions caused by wild-type members of the family Enterobacte-
riaceae. To assess this possibility, an international collection
of recently collected gram-positive and -negative pathogens
(1,149 strains) that contained organisms with well-character-
ized mechanisms of resistance or with the phenotypic expres-
sion of resistance according to the MICs was selected. All tests
were performed by reference Clinical and Laboratory Stan-
dards Institute (CLSI; formerly NCCLS) methods with appro-
priate medium supplements for fastidious streptococci (2 to
5% lysed horse blood) and Haemophilus sp. strains (Haemophi-
lus test medium formulation) (3, 4).
(This paper was presented in part in posters F1-0479 and
F1-0480 at the 46th Interscience Conference on Antimicrobial
Agents and Chemotherapy, San Francisco, CA, September
2006.)
MATERIALS AND METHODS
Bacterial strains. A total of 1,149 strains recently collected (2005 to 2007)
from infected patients worldwide were studied, with a balance of isolates from
Europe, the Asia-Pacific, and the Americas (North and South America). The
following major species were sampled: S. pneumoniae (n  112; 62 penicillin
nonsusceptible), Streptococcus pyogenes (n  30), Streptococcus agalactiae (n 
30), Staphylococcus aureus (n  90; 60 methicillin-resistant S. aureus [MRSA]
strains and 30 community-acquired S. aureus [CA-MRSA] strains), coagulase-
negative staphylococci (CoNS; n  60), enterococci (n  173; 62 vancomycin-
resistant enterococci and 10 linezolid-resistant enterococci), Listeria monocyto-
genes (n  10), H. influenzae (n  80; 30 -lactamase-positive strains and 10
-lactamase-negative and ampicillin-resistant [BLNAR] strains), Haemophilus
parainfluenzae (n  30), M. catarrhalis (n  29; 19 -lactamase-positive strains),
Bordetella pertussis (n  12), members of the family Enterobacteriaceae (n  323;
38 species), Pseudomonas aeruginosa (n  40), Acinetobacter spp. (n  40; 5
species), S. maltophilia (n  30), and Neisseria gonorrhoeae (n  60; 40 cipro-
floxacin-nonsusceptible strains). Numerous subsets of wild-type strains and
strains with defined resistance mechanisms or phenotypes in each genus or
species group were tested.
Susceptibility testing methods. DC-159a and levofloxacin standard powders
were supplied by Daiichi Pharmaceutical Co., Ltd. All other agents were ob-
tained from domestic (U.S.) manufacturers. The reference methods described by
the CLSI were used throughout the study (3, 4). Gonococci were tested by the
agar dilution method on GC agar base with the defined supplement (3, 4). The
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interpretive criteria of CLSI standard M100-S18 (4) were used, where available,
to determine the susceptibilities of the isolates to the comparison agents (24
antimicrobials). The PCR methods described by Mutnick et al. (11) were used to
determine the 23S rRNA mutations (G2576T) associated with the linezolid
resistance found in the enterococci.
Quality control was ensured by the use of the following strains: S. aureus
ATCC 29213, Enterococcus faecalis ATCC 29212, Escherichia coli ATCC 25922
and ATCC 35218, P. aeruginosa ATCC 27853, H. influenzae ATCC 49247 and
ATCC 49766, S. pneumoniae ATCC 49619, and N. gonorrhoeae ATCC 49226. All
quality control test results were within published CLSI ranges (4).
RESULTS
When the 107 pneumococci were subcategorized by their
susceptibilities to penicillin (Table 1), the DC-159a MIC90
remained unaffected at 0.12 g/ml. This potency was equal to
that of moxifloxacin and eightfold greater than that of levo-
floxacin. The DC-159a MIC results for the levofloxacin-non-
susceptible S. pneumoniae strains were generally increased 8-
to 16-fold, but all MICs remained 2 g/ml. Beta-hemolytic
streptococci were very susceptible to DC-159a, with MIC50s
and MIC90s of 0.12 g/ml. This potency was slightly greater
than that of moxifloxacin and eightfold greater than that of
levofloxacin (MIC90, 1 g/ml).
Most of the antimicrobials tested were active against the H.
influenzae strains (Table 1). The exceptions were ampicillin
against -lactamase-producing strains, azithromycin (rate of
nonsusceptibility, 2.5 to 3.4%), cefuroxime (2.5%), tetracycline
(6.7%), and trimethoprim-sulfamethoxazole (20.0 to 22.5%).
All fluoroquinolones were very active against H. influenzae,
with MIC90s ranging from 0.015 to 0.12 g/ml. The DC-
159a MIC90s for the H. influenzae strains were 0.015 and 0.03
g/ml, with the highest values being for the -lactamase-pos-
itive isolates. The 10 BLNAR strains had very low DC-159a
MICs that ranged from 0.008 to 0.015 g/ml. The H. parain-
fluenzae strains were approximately fourfold less susceptible to
DC-159a than the H. influenzae strains. This difference was
also observed for the other fluoroquinolones tested (Table 1).
The M. catarrhalis strains were very susceptible to DC-159a,
with MIC50s and MIC90s of 0.03 g/ml, regardless of whether
they produced a -lactamase (Table 1).
Table 2 lists the activity of DC-159a against 150 isolates of
staphylococci. DC-159a exhibited potent activity against meth-
icillin (oxacillin)-susceptible S. aureus (MSSA) strains, with
MIC50s and MIC90s of only 0.03 g/ml. This level of activity
was 16-fold greater than that of ciprofloxacin but 2-fold less
than that of gemifloxacin (MIC90, 0.015 g/ml). MRSA strains
derived from patients with nosocomial infections showed the
greatest susceptibility to DC-159a (MIC90, 2 g/ml). However,
the range of DC-159a MICs was 32- to 64-fold greater than
that for MSSA strains (0.015 to 0.06 g/ml for MRSA strains
versus 0.5 to 4 g/ml for MSSA strains). None of these MRSA
strains were susceptible at the CLSI breakpoint concentrations
of the comparison, marketed fluoroquinolones. The activity of
DC-159a against 30 well-characterized isolates from patients
with CA-MRSA infection (USA300-0114 and its variants) was
tested, and the MIC50 and MIC90 results for these strains were
identical to those for the MSSA strains (Table 2). The CA-
MRSA strains had a documented virulence island (Panton-
Valentine leukocidin positive), staphylococcal chromosomal
cassette mec type IVa, and agrI. Only 30% of the coagulase-
negative staphylococcal strains were oxacillin susceptible, and
the DC-159a MICs ranged from 0.03 to 0.5 g/ml (5 log2
dilutions steps). The activity of DC-159a against a large num-
ber of Staphylococcus saprophyticus strains (n 30) was tested,
with complete activity being achieved at 0.5 g/ml. Overall,
among the five groups of staphylococci tested, DC-159a at
0.5 g/ml inhibited all isolates in four of the groups (the
exception was the nosocomial MRSA group). DC-159a showed
a potency most similar to that of gemifloxacin (MIC90 range,
0.016 to 2 g/ml) and markedly greater than the potencies of
the other fluoroquinolones tested.
With one exception, each group of enterococci tested (Table
2) contained a mixture of strains best described as wild type
(DC-159a MIC range, 0.06 to 0.5 g/ml) and drug-resistant
mutants (DC-159a MIC range, 2 to 8 g/ml). The DC-159a
MIC of 1 g/ml appears to separate these isolates into two
groups that have modal MICs of 0.12 and 4 g/ml, respectively.
Eighty percent of the vancomycin-susceptible E. faecalis strains
were ciprofloxacin susceptible (wild-type MIC distributions),
and among these strains, the potency rank was as follows:
gemifloxacin (MIC90, 0.03 g/ml)  DC-159a (MIC90, 0.12
g/ml)  gatifloxacin  moxifloxacin (MIC90, 0.25 g/ml) 
ciprofloxacin  levofloxacin (MIC90, 0.5 g/ml). The largest
number of mutant (fluoroquinolone-resistant) enterococcal
phenotypes was encountered among the vancomycin-resistant
isolates (53 of 62 strains) and the linezolid-resistant isolates
(10 of 10 strains).
E. coli wild-type isolates (90% of which were susceptible to
ciprofloxacin) were equally susceptible to DC-159a and levo-
floxacin (MIC50s, 0.03 g/ml) (Table 3). In contrast, E. coli
strains producing extended-spectrum -lactamase (ESBL) en-
zymes were more likely to be fluoroquinolone resistant, and
the DC-159a and levofloxacin MIC50s were 1 doubling dilution
higher than those for the wild type (Table 2). The wild-type
Klebsiella spp. were highly susceptible to ciprofloxacin (90%
susceptible; MIC50s, 0.03 g/ml) and DC-159a (MIC50
range, 0.03 to 0.5 g/ml). Ten K. pneumoniae strains harboring
a KPC-type serine carbapenemase were tested (Table 3), and
only two strains had DC-159a MICs of 2 g/ml.
Table 3 also illustrates the activity of DC-159a against 20
Proteus mirabilis strains, 2 of which produced a CTX-M-type
ESBL, as determined by molecular testing. DC-159a had ac-
tivity (MIC50, 0.25 g/ml) equal to the activities of gatifloxacin
and moxifloxacin; but it was less active by weight (fourfold)
than levofloxacin, gemifloxacin, and ciprofloxacin. With the
current CLSI susceptibility breakpoints (4), susceptibilities of
the P. mirabilis strains to the marketed fluoroquinolones
showed marked variations (20%), with the ranking being as
follows: levofloxacin  gatifloxacin  ciprofloxacin  gemi-
floxacin (moxifloxacin does not have a published breakpoint).
Among the Citrobacter spp. (20 of 30 of the strains were
Citrobacter freundii strains), Enterobacter spp. (26 of 33 of the
strains were Enterobacter cloacae), and the S. marcescens
strains, significant differences in activity were observed when
DC-159a was tested against wild-type strains and various
strains with defined mechanisms of resistance (Table 3). The
DC-159a MIC90s for the wild-type strains ranged from 0.5 to 2
g/ml, whereas they ranged from 1 to 8 g/ml for the resistant
subsets of strains. The activity of DC-159a was comparable to
the activities of the other fluoroquinolones tested against these
isolates of the family Enterobacteriaceae, regardless of the core-
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TABLE 1. Activity of DC-159a tested by reference CLSI methods against 323 strains of streptococci and gram-negative pathogens associated
with respiratory tract infections
Organism (no. of strains tested)/
antimicrobial agent
MIC (g/ml) % Susceptible/
% resistanta:50% 90% Range
S. pneumoniae
Penicillin susceptible (30)
DC-159a 0.12 0.12 0.06–0.25 b/
Gatifloxacin 0.25 0.25 0.06–0.5 100.0/0.0
Gemifloxacin 0.015 0.015 0.015–0.03 100.0/0.0
Levofloxacin 1 1 0.5–1 100.0/0.0
Moxifloxacin 0.12 0.12 0.03–0.25 100.0/0.0
Ciprofloxacin 1 2 0.25–2 /
Erythromycin 0.25 0.25 0.25–32 96.7/3.3
Clindamycin 0.25 0.25 0.25–2 96.7/3.3
Penicillin intermediate (30)
DC-159a 0.06 0.12 0.06–0.12 /
Gatifloxacin 0.25 0.25 0.12–1 100.0/0.0
Gemifloxacin 0.015 0.03 0.015–0.06 100.0/0.0
Levofloxacin 1 1 0.5–1 100.0/0.0
Moxifloxacin 0.12 0.12 0.06–0.5 100.0/0.0
Ciprofloxacin 1 2 0.5–2 /
Erythromycin 2 32 0.25–32 43.3/53.3
Clindamycin 0.25 2 0.25–2 73.3/26.7
Penicillin resistant (32)
DC-159a 0.12 0.12 0.06–0.12 /
Gatifloxacin 0.25 0.5 0.25–1 100.0/0.0
Gemifloxacin 0.015 0.03 0.015–0.03 100.0/0.0
Levofloxacin 1 1 0.5–2 100.0/0.0
Moxifloxacin 0.12 0.25 0.06–1 100.0/0.0
Ciprofloxacin 1 2 0.5–4 /
Erythromycin 4 32 0.25–32 37.5/62.5
Clindamycin 0.25 2 0.25–2 56.3/43.8
Levofloxacin nonsusceptible (20)
DC-159a 0.5 1 0.25–2 /
Gatifloxacin 4 4 1–4 10.0/65.0
Gemifloxacin 0.12 0.25 0.06–1 65.0/10.0
Moxifloxacin 2 4 0.25–4 35.0/20.0
Ciprofloxacin 4 4 4–4 /
Erythromycin 0.25 2 0.25–8 60.0/40.0
Clindamycin 0.25 2 0.25–2 75.0/20.0
-Hemolytic streptococci
Group A (30)
DC-159a 0.12 0.12 0.06–0.12 /
Gatifloxacin 0.25 0.25 0.12–0.5 100.0/0.0
Gemifloxacin 0.015 0.03 0.008–0.06 /
Levofloxacin 0.5 1 0.25–2 100.0/0.0
Moxifloxacin 0.12 0.25 0.06–0.25 /
Ciprofloxacin 0.5 0.5 0.25–2 /
Penicillin 0.015 0.015 0.015 100.0/
Erythromycin 0.06 4 0.06–8 86.7/13.3
Clindamycin 0.06 0.06 0.06–8 96.7/3.3
Group B (30)
DC-159a 0.12 0.12 0.06–0.25 /
Gatifloxacin 0.25 0.25 0.12–0.5 100.0/0.0
Gemifloxacin 0.015 0.03 0.008–0.06 /
Levofloxacin 1 1 0.5–1 100.0/0.0
Moxifloxacin 0.12 0.25 0.06–0.25 /
Ciprofloxacin 0.5 1 0.25–1 /
Penicillin 0.06 0.12 0.015–0.12 100.0/
Erythromycin 0.06 2 0.06–8 76.7/23.3
Clindamycin 0.06 0.06 0.06–8 90.0/10.0
Continued on following page
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TABLE 1—Continued
Organism (no. of strains tested)/
antimicrobial agent
MIC (g/ml) % Susceptible/
% resistanta:50% 90% Range
H. influenzae
-Lactamase negative (40)
DC-159a 0.008 0.015 0.008–0.015 /
Gatifloxacin 0.03 0.03 0.03 100.0/
Gemifloxacin 0.015 0.015 0.015 100.0/
Levofloxacin 0.015 0.015 0.008–0.03 100.0/
Moxifloxacin 0.03 0.03 0.03 100.0/
Ciprofloxacin 0.12 0.12 0.12 100.0/
Amoxicillin-clavulanic acid 0.5 1 0.25–2 100.0/0.0
Azithromycin 1 2 0.5–16 97.5/
-Lactamase positive (30)
DC-159a 0.015 0.03 0.004–0.03 /
Gatifloxacin 0.03 0.03 0.03 100.0/
Gemifloxacin 0.015 0.015 0.015 100.0/
Levofloxacin 0.015 0.015 0.008–0.03 100.0/
Moxifloxacin 0.03 0.03 0.03–0.06 100.0/
Ciprofloxacin 0.12 0.12 0.12 100.0/
Amoxicillin-clavulanic acid 1 1 1 100.0/0.0
Azithromycin 1 2 0.5–4 96.7/
-Lactamase negative, ampicillin
resistant (10)c
DC-159a 0.015 0.015 0.008–0.015 /
Gatifloxacin 0.03 0.03 0.03 100.0/
Gemifloxacin 0.12 0.12 0.12 100.0/
Levofloxacin 0.015 0.015 0.015 100.0/
Moxifloxacin 0.03 0.03 0.03 100.0/
Ciprofloxacin 0.12 0.12 0.12 100.0/
Ampicillin 2 2 2–4 0.0/10.0
Amoxicillin-clavulanic acid 4 4 2–8 90.0/10.0
Azithromycin 1 1 0.5–1 100.0/
H. parainfluenzae (30)
DC-159a 0.06 0.12 0.008–0.25 /
Gatifloxacin 0.03 0.03 0.03–0.12 100.0/
Gemifloxacin 0.12 0.12 0.12 100.0/
Levofloxacin 0.03 0.06 0.015–0.12 100.0/
Moxifloxacin 0.03 0.12 0.03–0.5 100.0/
Ciprofloxacin 0.25 0.25 0.25 100.0/
Ampicillin 1 2 1–4 86.7/10.0
Amoxicillin-clavulanic acid 2 2 2–4 100.0/0.0
Azithromycin 0.5 2 0.12–2 100.0/
M. catarrhalis
-Lactamase negative (10)
DC-159a 0.03 0.03 0.015–0.03 /
Gatifloxacin 0.03 0.03 0.03 /
Gemifloxacin 0.12 0.12 0.12 /
Levofloxacin 0.03 0.03 0.015–0.03 /
Moxifloxacin 0.06 0.06 0.03–0.06 /
Ciprofloxacin 0.12 0.12 0.12 /
Penicillin 0.03 0.03 0.03–0.06 /
Amoxicillin-clavulanic acid 0.06 0.06 0.06 /
Erythromycin 0.25 0.25 0.25 /
-Lactamase positive (19)
DC-159a 0.03 0.03 0.015–0.03 /
Gatifloxacin 0.03 0.03 0.03–0.06 /
Gemifloxacin 0.12 0.12 0.12 /
Levofloxacin 0.03 0.03 0.015–0.03 /
Moxifloxacin 0.06 0.06 0.03–0.06 /
Ciprofloxacin 0.12 0.12 0.12 /
Continued on following page
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sistance of the isolates analyzed (Table 3). Only the carbapen-
ems (imipenem) and amikacin showed wider spectra of activity
against these groups of the Enterobacteriaceae.
DC-159a was active (MIC50 and MIC90, 0.06 g/ml) against
all wild-type isolates of Salmonella spp. at 0.25 g/ml (Table
3). This level of activity was equal to the levels of activity of
all other fluoroquinolones tested. One strain had a CMY-2 -
lactamase that produced resistance to extended-spectrum
cephems. Against the more resistant salmonellae, DC-159a
MICs were four- to eightfold higher, consistent with a first-step
QRDR mutation. All other fluoroquinolone MICs were simi-
larly elevated, but none of the isolates were judged to be
resistant according to the CLSI breakpoint criteria (4). The
Shigella sp. isolates were very susceptible to DC-159a and all
fluoroquinolones tested. The test results for strains of five
other species of the Enterobacteriaceae (Edwardsiella tarda
[one strain], Escherichia vulneris [two strains], Hafnia alvei
[four strains], Leclercia adecarboxylata [one strain], Pantoea
agglomerans [one strain], and Serratia plymuthica [one strain])
showed variable patterns of resistance among the organisms;
however, DC-159a inhibited all isolates at 1 g/ml (MIC50,
0.06 g/ml) (data not shown).
All P. aeruginosa isolates (30 strains; Table 3) were cipro-
floxacin susceptible, with a single strain having a DC-159a and
a gatifloxacin MIC of 4 g/ml (potential intermediate suscep-
tibility); however, three strains (10% of strains) had moxifloxa-
cin MICs of 4 g/ml. DC-159a was twofold less active than
levofloxacin by use of the MIC50 (0.5 g/ml) and MIC90 (2
g/ml) results. Other than the fluoroquinolones, only the ami-
noglycosides inhibited more than 90% of the P. aeruginosa
strains. Against the ciprofloxacin-resistant P. aeruginosa strains
(10 strains), the DC-159a MICs ranged from 4 to 8 g/ml.
None of the fluoroquinolones tested were active, and only
three of the antimicrobials tested (ceftazidime [which was ac-
tive against 50% of the isolates], imipenem [50%], and amika-
cin [60%]) were active against 50% of these P. aeruginosa
strains.
The activities of the fluoroquinolones (MIC90s) against the
wild-type Acinetobacter sp. strains varied over a narrow range
from 0.12 g/ml (DC-159a, gatifloxacin, moxifloxacin) to 0.25
g/ml (levofloxacin, ciprofloxacin). Acinetobacters resistant to
the commonly used fluoroquinolones demonstrated cross-re-
sistance and coresistance to -lactams (except carbapenems)
and some other drug classes. DC-159a was the most active of
the agents tested against S. maltophilia (30 strains; Table 3).
The activity of DC-159a was compared to the activities of
five agents against 60 gonococci with various ciprofloxacin sus-
ceptibility categories according to the CLSI (4) breakpoint
criteria (Table 4). The DC-159a MICs increased (as did the
levofloxacin MICs) as the ciprofloxacin MICs increased. The
DC-159a MIC ranges for ciprofloxacin-susceptible, -interme-
diate, and -resistant strains were 0.008 to 0.015, 0.03 to 0.12,
and 0.25 to 1 g/ml, respectively. The levels of resistance to the
-lactams and tetracycline were also elevated among the cipro-
floxacin-resistant strains. Overall, the DC-159a MICs were
greater than or equal to eightfold lower than those of cipro-
floxacin or levofloxacin against gonococcal strains with muta-
tions in the QRDR.
DISCUSSION
The emergence of resistance to a wide range of antimicro-
bials among pathogens in medical centers and in the outpatient
setting has posed serious therapeutic challenges. Examples of
the most problematic pathogens have been (i) CA-MRSA
strains, (ii) glycopeptide-nonsusceptible staphylococci, (iii)
MDR P. aeruginosa and Acinetobacter sp. strains, (iv) vanco-
mycin-resistant enterococci, (v) strains with novel -lactamases
with wide substrate affinities, and (vi) MDR S. pneumoniae
strains (1, 6, 12–14). Concurrent with this resistance has been
the introduction of several newer fluoroquinolones (10) pri-
marily directed against community-acquired respiratory tract
infections and novel drug classes (oxazolidinones) that are
active among resistant gram-positive pathogens (5). These in-
troductions have been associated with evolving resistance due
to ribosomal target and QRDR mutations (11, 12). The
QRDR mutations in S. pneumoniae elevate the MICs of the
currently available fluoroquinolone to levels associated with
clinical failure (7), and similar QRDR modifications in S. au-
reus (8) present therapeutic obstacles to the use of existing
TABLE 1—Continued
Organism (no. of strains tested)/
antimicrobial agent
MIC (g/ml) % Susceptible/
% resistanta:50% 90% Range
Penicillin 2 4 0.25–4 /
Amoxicillin-clavulanic acid 0.25 0.25 0.25 /
Erythromycin 0.25 0.25 0.25 /
B. pertussis (12)
DC-159a 0.008 0.015 0.008–0.015 /
Levofloxacin 0.06 0.06 0.03–0.06 100.0/0.0
Ciprofloxacin 0.03 0.03 0.015–0.03 100.0/0.0
Azithromycin 0.06 0.12 0.03–0.12 /
Clarithromycin 0.06 0.12 0.03–0.25 /
Erythromycin 0.12 0.12 0.06–0.25 /
Clindamycin 0.25 0.25 0.06–0.5 /
a Criteria published by the CLSI (4).
b , no breakpoint criteria have been established for this category.
c Ampicillin at 2 g/ml, according to the definition of BLNAR.
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TABLE 2. Antimicrobial activity of DC-159a against 283 strains of other gram-positive species isolates by CLSI methods
Organism (no. of strains tested)/antimicrobial agent
MIC (g/ml) % Susceptible/
% resistanta50% 90% Range
S. aureus
Oxacillin susceptible (30)
DC-159a 0.03 0.03 0.015–0.06 b/
Gatifloxacin 0.06 0.12 0.03–0.12 100.0/0.0
Levofloxacin 0.12 0.25 0.06–0.25 100.0/0.0
Moxifloxacin 0.03 0.06 0.03–0.12 100.0/0.0
Ciprofloxacin 0.25 0.5 0.06–0.5 100.0/0.0
Linezolid 1 2 0.5–2 100.0/
Tetracycline 2 4 2–8 90.0/10.0
Trimethoprim-sulfamethoxazole 0.5 0.5 0.5 100.0/0.0
Clindamycin 0.12 0.12 0.06–0.5 100.0/0.0
Erythromycin 0.25 8 0.25–8 83.3/16.7
Oxacillin resistant, nosocomial (30)
DC-159a 1 2 0.5–4 /
Gatifloxacin 4 4 1–4 0.0/96.7
Levofloxacin 8 8 4–8 0.0/100.0
Moxifloxacin 2 4 1–4 0.0/83.3
Ciprofloxacin 4 4 4 0.0/100.0
Linezolid 1 2 1–2 100.0/
Tetracycline 2 8 2–8 80.0/20.0
Trimethoprim-sulfamethoxazole 0.5 2 0.5–2 86.7/13.3
Clindamycin 8 8 0.06–8 26.7/70.0
Erythromycin 8 8 0.25–8 6.7/93.3
Oxacillin resistant, community acquired (30)
DC-159a 0.03 0.03 0.008–0.5 /
Gatifloxacin 0.06 0.12 0.03–2 93.3/6.7
Levofloxacin 0.12 0.25 0.12–4 93.3/6.7
Moxifloxacin 0.03 0.06 0.03–1 93.3/0.0
Ciprofloxacin 0.25 0.5 0.25–4 93.3/6.7
Linezolid 2 2 1–2 100.0/
Tetracycline 4 4 4–8 90.0/10.0
Trimethoprim-sulfamethoxazole 0.5 0.5 0.5 100.0/0.0
Clindamycin 0.12 0.12 0.06–0.25 100.0/0.0
Erythromycin 8 8 8 0.0/100.0
CoNS (30)c
DC-159a 0.06 0.5 0.03–0.5 /
Gatifloxacin 0.25 2 0.06–4 60.0/16.7
Levofloxacin 0.25 8 0.12–8 60.0/26.7
Moxifloxacin 0.25 2 0.03–4 63.3/16.7
Ciprofloxacin 0.5 4 0.12–4 56.7/43.3
Linezolid 1 1 0.5–2 100.0/
Tetracycline 2 8 2–8 86.7/13.3
Trimethoprim-sulfamethoxazole 0.5 2 0.5–2 66.7/33.3
Clindamycin 0.06 8 0.06–8 83.3/16.7
Erythromycin 0.25 8 0.06–8 53.3/43.3
Oxacillin 2 2 0.25–2 30.0/70.0
S. saprophyticus (30)
DC-159a 0.12 0.25 0.03–0.5 /
Gatifloxacin 0.25 2 0.06–2 83.3/13.3
Levofloxacin 0.5 2 0.12–8 86.7/10.0
Moxifloxacin 0.12 1 0.03–2 83.3/6.7
Ciprofloxacin 0.5 4 0.12–4 83.3/16.7
Linezolid 1 2 0.5–2 100.0/
Tetracycline 2 8 2–8 76.7/23.3
Trimethoprim-sulfamethoxazole 0.5 2 0.5–2 86.7/13.3
Clindamycin 0.06 0.5 0.06–8 90.0/10.0
Erythromycin 0.25 8 0.12–8 60.0/40.0
Oxacillin 1 2 0.5–2 0.0/100.0
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TABLE 2—Continued
Organism (no. of strains tested)/antimicrobial agent
MIC (g/ml) % Susceptible/
% resistanta50% 90% Range
E. faecalis
Vancomycin susceptible (30)
DC-159a 0.12 4 0.06–8 /
Gatifloxacin 0.25 4 0.12–4 80.0/20.0
Levofloxacin 0.5 8 0.25–8 80.0/20.0
Ciprofloxacin 0.5 4 0.25–4 80.0/20.0
Ampicillin 1 2 1–4 100.0/0.0
Linezolid 1 2 0.5–2 100.0/0.0
Gentamicin-HL 500 1000 500–1000 70.0/30.0
Tetracycline 8 8 2–8 23.3/76.7
Erythromycin 2 8 0.25–8 13.3/46.7
Vancomycin resistant (30)
DC-159a 4 4 0.12–8 /
Gatifloxacin 4 4 0.12–4 6.7/93.3
Levofloxacin 8 8 0.5–8 6.7/93.3
Ciprofloxacin 4 4 0.5–4 6.7/93.3
Ampicillin 2 4 1–16 96.7/3.3
Linezolid 1 2 1–2 100.0/0.0
Gentamicin-HLe 1000 1000 500–1000 30.0/70.0
Tetracycline 8 8 2–8 33.3/66.7
Erythromycin 8 8 2–8 0.0/96.7
Enterococcus faecium
Vancomycin susceptible (31)
DC-159a 1 8 0.06–8 /
Gatifloxacin 2 4 0.25–4 51.6/45.2
Levofloxacin 2 8 0.25–8 51.6/45.2
Ciprofloxacin 4 4 0.25–4 25.8/58.1
Ampicillin 16 16 1–16 41.9/58.1
Linezolid 2 2 1–2 100.0/0.0
Gentamicin-HL 500 1000 500–1000 77.4/22.6
Tetracycline 2 8 2–8 58.1/38.7
Erythromycin 8 8 0.25–8 6.5/67.7
Vancomycin resistant (32)
DC-159a 8 8 0.25–8 /
Gatifloxacin 4 4 0.5–4 18.8/81.3
Levofloxacin 8 8 2–8 18.8/81.3
Ciprofloxacin 4 4 1–4 3.1/87.5
Ampicillin 16 16 2–16 3.1/96.9
Linezolid 2 2 1–2 100.0/0.0
Gentamicin-HL 500 1000 500–1000 65.6/34.4
Tetracycline 8 8 2–8 40.6/59.4
Erythromycin 8 8 1–8 0.0/87.5
Enterococcus spp., linezolid resistant (10)d
DC-159a 4 8 2–8 /
Gatifloxacin 4 4 4 0.0/100.0
Levofloxacin 8 8 8 0.0/100.0
Ciprofloxacin 4 4 4 0.0/100.0
Ampicillin 1 16 1–16 50.0/50.0
Vancomycin 16 16 0.5–16 40.0/60.0
Gentamicin-HL 500 1000 500–1000 60.0/40.0
Tetracycline 8 8 2–8 30.0/70.0
Erythromycin 8 8 2–8 0.0/90.0
a Criteria published by the CLSI (4). The determination of -lactam susceptibility should be directed by the oxacillin test results.
b , no breakpoint criteria have been established for this category.
c CoNS include Staphylococcus auricularis (four strains), S. capitis (three strains), coagulase-negative staphylococcus (one strain), S. cohnii (one strain), S. epidermidis
(five strains), S. haemolyticus (three strains), S. hominis (two strains), S. intermedius (two strains), S. lugdunensis (two strains), S. schleiferi (one strain), S. sciuri (one
strain), S. simulans (one strain), S. warnerii (two strains), and S. xylosis (two strains).
d Includes Enterococcus faecalis (five strains) and E. faecium (five strains).
e HL, high level.
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TABLE 3. Activity of DC-159a against 423 strains of gram-negative bacilli by reference (CLSI) methods
Organism (no. of strains tested)/
antimicrobial agent
MIC (g/ml) % Susceptible/
% resistanta50% 90% Range
E. coli
Wild type (20)
DC-159a 0.03 0.12 0.015–8 b/
Gatifloxacin 0.03 0.12 0.03–4 90.0/5.0
Gemifloxacin 0.008 0.06 0.004–2 90.0/10.0
Levofloxacin 0.03 0.25 0.015–8 90.0/5.0
Moxifloxacin 0.03 0.25 0.03–4 /
Ciprofloxacin 0.03 0.12 0.03–4 90.0/10.0
Ceftriaxone 0.25 0.25 0.25–16 95.0/0.0
Imipenem 0.5 0.5 0.5 100.0/0.0
Amikacin 2 2 0.5–4 100.0/0.0
ESBL phenotype (20)c
DC-159a 0.06 8 0.015–8 /
Gatifloxacin 0.03 4 0.03–4 70.0/20.0
Gemifloxacin 0.03 1 0.03–1 65.0/35.0
Levofloxacin 0.06 8 0.015–8 65.0/25.0
Moxifloxacin 0.06 4 0.03–4 /
Ciprofloxacin 0.25 2 0.25–2 65.0/35.0
Ceftriaxone 16 32 1–32 40.0/20.0
Imipenem 0.25 0.5 0.12–0.5 100.0/0.0
Amikacin 2 16 0.5–16 100.0/0.0
Klebsiella spp.
Wild type (20)d
DC-159a 0.12 1 0.03–8 /
Gatifloxacin 0.06 1 0.03–4 90.0/5.0
Gemifloxacin 0.03 0.5 0.015–2 85.0/10.0
Levofloxacin 0.06 1 0.03–8 90.0/5.0
Moxifloxacin 0.12 1 0.06–4 /
Ciprofloxacin 0.03 0.5 0.03–4 90.0/10.0
Ceftriaxone 0.25 32 0.25–32 85.0/10.0
Imipenem 0.5 0.5 0.5 100.0/0.0
Amikacin 1 8 0.5–32 95.0/0.0
ESBL phenotype (20)e
DC-159a 0.5 8 0.06–8 /
Gatifloxacin 0.5 4 0.03–4 65.0/20.0
Gemifloxacin 0.25 1 0.015–1 55.0/40.0
Levofloxacin 1 8 0.03–8 65.0/30.0
Moxifloxacin 0.5 4 0.06–4 /
Ciprofloxacin 1 2 0.015–2 55.0/40.0
Ceftriaxone 32 32 4–32 15.0/45.0
Imipenem 0.5 0.5 0.5–1 100.0/0.0
Amikacin 16 32 1–32 65.0/25.0
KPC producers (10)f
DC-159a 8 8 0.06–8 /
Gatifloxacin 4 4 0.03–4 20.0/80.0
Gemifloxacin 2 2 0.015–2 10.0/90.0
Levofloxacin 8 8 0.03–8 20.0/80.0
Moxifloxacin 4 4 0.06–4 /
Ciprofloxacin 4 4 0.03–4 10.0/90.0
Ceftriaxone 32 32 16–32 0.0/80.0
Imipenem 8 8 4–8 10.0/60.0
Amikacin 32 32 4–32 30.0/30.0
P. mirabilis (20)g
DC-159a 0.25 8 0.12–8 /
Gatifloxacin 0.5 4 0.06–4 75.0/20.0
Gemifloxacin 0.25 2 0.03–2 55.0/45.0
Levofloxacin 0.12 8 0.03–8 85.0/15.0
Moxifloxacin 1 4 0.12–4 /
Ciprofloxacin 0.12 2 0.03–2 65.0/15.0
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TABLE 3—Continued
Organism (no. of strains tested)/
antimicrobial agent
MIC (g/ml) % Susceptible/
% resistanta50% 90% Range
Ceftriaxone 0.25 32 0.25–32 80.0/10.0
Imipenem 1 2 0.5–4 100.0/0.0
Amikacin 4 4 2–32 95.0/5.0
Citrobacter spp.
Wild type (20)h
DC-159a 0.06 0.5 0.03–8 /
Gatifloxacin 0.03 0.5 0.03–4 90.0/0.0
Gemifloxacin 0.015 0.25 0.004–2 90.0/10.0
Levofloxacin 0.03 0.5 0.015–8 90.0/5.0
Moxifloxacin 0.06 1 0.03–4 /
Ciprofloxacin 0.03 0.5 0.03–4 90.0/10.0
Ceftriaxone 0.25 4 0.25–8 100.0/0.0
Imipenem 0.5 1 0.5–1 100.0/0.0
Amikacin 1 2 0.5–4 100.0/0.0
Ceftazidime resistant (10)i
DC-159a 0.12 1 0.06–2 /
Gatifloxacin 0.5 4 0.03–4 80.0/10.0
Gemifloxacin 0.03 1 0.008–2 70.0/20.0
Levofloxacin 0.06 1 0.03–4 90.0/0.0
Moxifloxacin 1 4 0.06–4 /
Ciprofloxacin 0.12 4 0.03–4 80.0/20.0
Ceftriaxone 32 32 16–32 0.0/20.0
Imipenem 0.5 1 0.5–4 100.0/0.0
Amikacin 2 4 1–32 90.0/10.0
Enterobacter spp.
Wild type (20)j
DC-159a 0.06 0.5 0.03–8 /
Gatifloxacin 0.03 0.12 0.03–4 95.0/5.0
Gemifloxacin 0.015 0.06 0.008–2 95.0/5.0
Levofloxacin 0.03 0.12 0.015–8 95.0/5.0
Moxifloxacin 0.06 0.25 0.03–4 /
Ciprofloxacin 0.03 0.06 0.03–4 95.0/5.0
Ceftriaxone 0.25 0.5 0.25–32 95.0/5.0
Imipenem 0.5 0.5 0.5–1 100.0/0.0
Amikacin 1 2 1–16 100.0/0.0
Ceftazidime resistant (13)k
DC-159a 0.5 8 0.06–8 /
Gatifloxacin 0.5 4 0.03–4 69.2/30.8
Gemifloxacin 0.12 2 0.008–2 76.9/23.1
Levofloxacin 0.25 8 0.03–8 76.9/23.1
Moxifloxacin 0.5 4 0.06–4 /
Ciprofloxacin 0.25 4 0.03–4 61.5/30.8
Ceftriaxone 32 32 4–32 23.1/61.5
Imipenem 0.5 2 0.5–4 100.0/0.0
Amikacin 2 8 0.5–32 92.3/7.7
Indole-positive Proteae (40)l
DC-159a 0.25 8 0.06–8 /
Gatifloxacin 0.12 4 0.03–4 75.0/20.0
Gemifloxacin 0.06 2 0.004–2 70.0/30.0
Levofloxacin 0.06 8 0.03–8 75.0/20.0
Moxifloxacin 0.25 4 0.06–4 /
Ciprofloxacin 0.03 4 0.03–4 72.5/27.5
Ceftriaxone 0.25 4 0.25–32 92.5/0.0
Imipenem 1 2 0.5–4 100.0/0.0
Amikacin 2 4 0.5–16 100.0/0.0
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TABLE 3—Continued
Organism (no. of strains tested)/
antimicrobial agent
MIC (g/ml) % Susceptible/
% resistanta50% 90% Range
S. marcescens
Wild type (20)
DC-159a 0.5 2 0.12–8 /
Gatifloxacin 0.25 2 0.12–4 90.0/5.0
Gemifloxacin 0.12 1 0.06–2 75.0/20.0
Levofloxacin 0.12 1 0.06–4 90.0/0.0
Moxifloxacin 0.5 4 0.25–4 /
Ciprofloxacin 0.06 1 0.06–4 90.0/10.0
Ceftriaxone 0.25 2 0.25–32 90.0/5.0
Imipenem 0.5 1 0.5–2 100.0/0.0
Amikacin 4 32 1–32 85.0/5.0
Ceftazidime resistant (10)
DC-159a 2 8 0.25–8 /
Gatifloxacin 2 4 0.12–4 50.0/30.0
Gemifloxacin 1 2 0.03–2 30.0/60.0
Levofloxacin 1 8 0.12–8 60.0/30.0
Moxifloxacin 2 4 0.12–4 /
Ciprofloxacin 1 4 0.06–4 50.0/50.0
Ceftriaxone 32 32 16–32 0.0/50.0
Imipenem 0.5 1 0.5–1 100.0/0.0
Amikacin 32 32 2–32 30.0/30.0
Salmonella spp.
Wild type (20)m
DC-159a 0.06 0.06 0.015–0.25 /
Gatifloxacin 0.03 0.06 0.03–0.25 100.0/0.0
Gemifloxacin 0.015 0.015 0.004–0.12 100.0/0.0
Levofloxacin 0.03 0.06 0.015–0.25 100.0/0.0
Moxifloxacin 0.06 0.12 0.03–0.5 /
Ciprofloxacin 0.03 0.03 0.03–0.25 100.0/0.0
Ceftriaxone 0.25 0.25 0.25–16 95.0/0.0
Imipenem 0.5 0.5 0.5 100.0/0.0
Amikacin 1 2 1–4 100.0/0.0
Resistant phenotype (10)n
DC-159a 0.25 0.5 0.06–1 /
Gatifloxacin 0.12 0.5 0.03–1 100.0/0.0
Gemifloxacin 0.06 0.25 0.008–0.25 100.0/0.0
Levofloxacin 0.25 0.5 0.03–1 100.0/0.0
Moxifloxacin 0.25 1 0.03–2 /
Ciprofloxacin 0.12 0.25 0.03–1 100.0/0.0
Ceftriaxone 0.25 32 0.25–32 70.0/0.0
Imipenem 0.5 0.5 0.5 100.0/0.0
Amikacin 2 2 1–2 100.0/0.0
Shigella spp. (40)o
DC-159a 0.03 0.06 0.015–0.25 /
Gatifloxacin 0.03 0.03 0.03–0.25 100.0/0.0
Gemifloxacin 0.008 0.015 0.004–0.12 100.0/0.0
Levofloxacin 0.03 0.06 0.015–0.25 100.0/0.0
Moxifloxacin 0.03 0.06 0.03–0.25 /
Ciprofloxacin 0.03 0.03 0.03–0.25 100.0/0.0
Ceftriaxone 0.25 0.25 0.25 100.0/0.0
Imipenem 0.5 0.5 0.5 100.0/0.0
Amikacin 4 4 1–8 100.0/0.0
P. aeruginosa
Wild type (30)
DC-159a 0.5 2 0.25–4 /
Gatifloxacin 0.5 1 0.12–4 96.7/0.0
Levofloxacin 0.25 1 0.12–2 100.0/0.0
Moxifloxacin 1 2 0.25–4 /
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TABLE 3—Continued
Organism (no. of strains tested)/
antimicrobial agent
MIC (g/ml) % Susceptible/
% resistanta50% 90% Range
Ciprofloxacin 0.12 0.25 0.03–1 100.0/0.0
Ceftazidime 2 16 1–16 86.7/6.7
Cefepime 2 16 1–16 86.7/6.7
Imipenem 1 8 0.5–8 83.3/13.3
Amikacin 2 4 0.5–32 93.3/3.3
Ciprofloxacin resistant (10)
DC-159a 8 8 4–8 /
Gatifloxacin 4 4 4–4 0.0/90.0
Levofloxacin 8 8 8–8 0.0/100.0
Ciprofloxacin 4 4 4–4 0.0/100.0
Ceftazidime 4 16 2–16 50.0/40.0
Cefepime 16 16 8–16 40.0/20.0
Imipenem 2 8 0.5–8 50.0/40.0
Amikacin 8 32 2–32 60.0/40.0
Acinetobacter spp.
Wild type (30)p
DC-159a 0.06 0.12 0.015–1 /
Gatifloxacin 0.03 0.12 0.03–0.5 100.0/0.0
Levofloxacin 0.06 0.25 0.03–0.5 100.0/0.0
Ciprofloxacin 0.12 0.25 0.06–0.5 100.0/0.0
Ceftazidime 4 16 1–16 76.7/10.0
Cefepime 2 16 0.25–16 86.7/6.7
Imipenem 0.5 0.5 0.5–4 100.0/0.0
Amikacin 2 8 0.25–32 93.3/6.7
Ciprofloxacin and levofloxacin
resistant (10)q
DC-159a 8 8 4–8 /
Gatifloxacin 4 4 4–4 0.0/90.0
Levofloxacin 8 8 8–8 0.0/100.0
Ceftazidime 16 16 8–16 10.0/80.0
Cefepime 16 16 16–16 0.0/50.0
Imipenem 1 8 0.5–8 80.0/20.0
Amikacin 16 32 4–32 50.0/40.0
S. maltophilia (30)
DC-159a 0.12 0.5 0.03–4 /
Gatifloxacin 0.5 2 0.12–4 90.0/6.7
Levofloxacin 0.5 2 0.06–8 93.3/6.7
Ciprofloxacin 1 4 0.25–4 53.3/16.7
Ceftazidime 8 16 1–16 50.0/43.3
Cefepime 16 16 4–16 20.0/56.7
Amikacin 32 32 4–32 6.7/86.7
a Criteria published by the CLSI (4).
b , no breakpoint criteria have been established for this category or agent.
c Includes strains harboring TEM-1, TEM-3, TEM-4, TEM-5, TEM-6, TEM-7, TEM-8, SHV-5, CTX-M2, CMY-2 (8 strains), or FOX-5 (3 strains).
d Includes Klebsiella oxytoca (5 strains) and K. pneumoniae (15 strains).
e Includes Klebsiella pneumoniae (20 strains) with mobile AmpC enzymes (9 strains), CTX-M2 (4 strains), SHV-5 (5 strains), SHV-7, and ESBL NOS.
f Includes Klebsiella pneumoniae (10 strains) harboring KPC NOS (4 strains), KPC-2 (5 strains), or KPC-3 (11 strains).
g CTX-M phenotypes (two strains).
h Includes Citrobacter braakii (1 strain), C. farmeri (1 strain), C. freundii (11 strains), and C. koseri (7 strains).
i Includes Citrobacter freundii (nine strains), and Citrobacter species (one strain).
j Includes Enterobacter aerogenes (4 strains) and E. cloacae (16 strains).
k Includes Enterobacter aerogenes (1 strain), E. cloacae (10 strains), E. gergoviae (1 strain), and Enterobacter species (1 strain).
l Includes Morganella morganii (10 strains), Proteus vulgaris (11 strains), Providencia rettgeri (9 strains), and Providencia stuartii (10 strains).
m Includes Salmonella group B (three strains), Salmonella group C (two strains), Salmonella group D (two strains), Salmonella species (eight strains), Salmonella
enterica serovar Typhi (two strains), and S. enterica serovar Typhimurium (three strains).
n Resistance to ampicillin, cephalosporins, tetracyclines, or trimethoprim-sulfamethoxazole. Includes S. enterica serovar Enteritidis (one strain), Salmonella group B
(one strain), Salmonella group C (one strain), S. enterica serovar Hadar (one strain), S. enterica serovar Heidelberg (one strain), S. enterica serovar Typhi (one strain),
S. enterica serovar Typhimurium (three strains), and S. enterica serovar Virchow (one strain).
o Includes Shigella boydii (4 strains), S. dysenteriae (3 strains), S. flexneri (14 strains), S. sonnei (16 strains), and Shigella species (3 strains).
p Includes Acinetobacter anitratus (1 strain), A. baumannii (14 strains), A. calcoaceticus (3 strains), A. junii (2 strains), A. lwoffii (8 strains), and Acinetobacter species (2 strains).
q Includes Acinetobacter baumannii (nine strains) and A. lwoffii (one strain).
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fluoroquinolones for the treatment of CA-MRSA or other
MRSA infections. Furthermore, the use of fluoroquinolones as
the treatment of choice for uncomplicated gonorrhea has been
negated by the high rates of resistance among gonococci in the
United States and worldwide (16).
In this study of the activity of DC-159a, DC-159a was shown
to possess a combination of antimicrobial qualities that may
overcome some of the deficiencies of current fluoroquinolones,
confirming the findings of earlier studies (2, 9). Against levo-
floxacin- or penicillin-resistant S. pneumoniae strains, DC-159a
had activity (MIC90 range, 0.12 to 1 g/ml) intermediate be-
tween that of gemifloxacin (MIC90 range, 0.03 to 0.25 g/ml)
and that of moxifloxacin (MIC90 range, 0.25 to 4 g/ml), and
DC-159a was also very potent against other species associated
with community-acquired respiratory tract infections (MIC
range, 0.015 to 0.12; MICs for all strains, 0.25 g/ml). DC-
159a was approximately 16-fold more active than ciprofloxacin
against staphylococci and showed the potential for use for the
treatment of endemic CA-MRSA strains and some mutants
with QRDR mutations. Gonococci resistant or intermediately
susceptible to ciprofloxacin had DC-159a MICs that ranged
from 0.03 to 1 g/ml. Finally, the overall potency of DC-159a
against members of the family Enterobacteriaceae (median
MIC50, 0.12 g/ml), P. aeruginosa (MIC50 for wild-type strains,
0.5 g/ml), and Acinetobacter spp. (MIC50 for wild-type strains,
0.06 g/ml) was most similar to that of levofloxacin, although
DC-159a was markedly more active against the S. maltophilia
strains (MIC50, 0.12 g/ml). We eagerly await the publication
of pharmacokinetic/pharmacodynamic results for DC-159a so
that predictive microbiological/clinical breakpoint concentra-
tions can be assigned (4, 15).
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